Bioanalytical Community

 View Only
  • 1.  Editing Calibration Curves in Quantitative Ligand Binding Assays

    Posted 03-13-2024 14:43

    Hi All,

    For editing a calibration curve (curve reprocessing) in quantitative ligand binding assays, if either LLOQ or ULOQ calibrator had to be masked, the assay limit shifts to the next lowest or highest point (The AAPS Journal (2018) 20: 22). In this case, should that next lowest or highest calibrator point assume the 25% RE or %CV acceptance criteria (like usual LLOQ or ULOQ acceptance criteria)? Thanks for your time.



    ------------------------------
    Md Zahir Uddin
    Research Scientist 2
    Charles River Laboratories
    Reno NV
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------


  • 2.  RE: Editing Calibration Curves in Quantitative Ligand Binding Assays

    Posted 03-14-2024 07:51

    Dear Zahir

    If the LLOQ or ULOQ is masked, the assay limit will shift to next lowest or highest calibrator value, respectively. This new value will have 20%RE and 20% CV as acceptance criteria. 

    Please also see the M10 Training material on ICH web page. 

    All the best

    Marianne 



    ------------------------------
    Marianne Scheel Fjording CEO
    Biolyzr Bioanalysis Excellence

    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------



  • 3.  RE: Editing Calibration Curves in Quantitative Ligand Binding Assays

    Posted 03-15-2024 15:09

    Hello Md Zahir Uddin, 

    Per ICH M10 guidance, Section 4.3.2: 

    "If the rejected calibration standard is the LLOQ, the new lower limit for this analytical run is the next lowest acceptable calibration standard of the calibration curve.  If the highest calibration standard is rejected, the new upper limit for this analytical run is the next acceptable highest calibration standard of the calibration curve.  The new lower and upper limit calibration standard will retain their original acceptance criteria (i.e. +/- 20%).  The revised calibration range should cover all QCs (low, medium and high).  The study samples outside of the revised assay range should be reanalysed."

    Hope this helps!

    --Heidi



    ------------------------------
    Heidi Mangus
    Associate Director, Bioanalytical & NonClinical Development Operations
    Disc Medicine
    Newtown PA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------



  • 4.  RE: Editing Calibration Curves in Quantitative Ligand Binding Assays

    Posted 03-18-2024 10:06

    Hi Zahir,

      Calibration standards immediately below or above your LQC and HQC must have the same acceptance criteria as LQC and HQC. If they don't, then your run fails, so sorry.

    Cheers!

    Robert



    ------------------------------
    Robert Kubiak PhD
    Senior Manager, R&D
    AstraZeneca PLC
    Gaithersburg MD
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------



  • 5.  RE: Editing Calibration Curves in Quantitative Ligand Binding Assays

    Community Leadership
    Posted 03-19-2024 09:45

    It's a fair question to ask. I agree with Robert, however, that you cannot expand the acceptable range for the calibrators functioning as the new run-specific ULOQ or LLOQ. Expanding the acceptable range for those calibrators would not ensure the assay is performing similarly to validation experiments.

    On a side note, this is another benefit of including anchor points for 4PL/5PL curves. If it is a true sporadic error, the anchor points can help the curve retain the correct shape rather than over-emphasizing the exact value of a calibrator that is now the highest or lowest signal in the curve fit, but was not originally intended to fill that role.



    ------------------------------
    Joleen White Ph.D.
    AAPS 2024 Global Health Community Chair
    Bioanalytical 101 Course Development
    Senior Bioassay Development Lead
    Gates Medical Research Institute
    Cambridge MA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------



  • 6.  RE: Editing Calibration Curves in Quantitative Ligand Binding Assays

    Posted 03-19-2024 10:00

    HI, I slightly disagree if I understand the question and answers correctly.

    If ULOQ fails, and HQC passes (with original criteria, not ULOQ criteria), the samples with concentrations up to HQC can be accepted, as the range of the curve is reduced, yet the curve up to HQC meets criteria set forth in validation. Only samples with concentrations above the passing HQCs could not be accepted as reliable and would need to be retested



    ------------------------------
    Michele Fiscella
    Vice President Translational & Bioanalytical Sciences
    REGENXBIO
    Rockville MD
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------



  • 7.  RE: Editing Calibration Curves in Quantitative Ligand Binding Assays

    Community Leadership
    Posted 03-19-2024 12:25

    Clarification always good. My reading of the question was to apply the ULOQ acceptance criterion to the new highest calibrator concentration. Based on your response, I think we are aligned.

    Your response reminded me of another question, however, that is related but I don't think was asked - can you extrapolate to concentrations outside the new calibrator range. Example, if the LLOQ standard is masked and the only standards below the LQC are anchor points, can you quantitate down to LQC if it passes. My position is that it is not allowed because you cannot extrapolate concentrations outside the calibrators with acceptance criteria. So we typically make sure we put 2 calibrators below LQC and above HQC to avoid rejecting runs if the LLOQ or ULOQ calibrators fail.



    ------------------------------
    Joleen White Ph.D.
    AAPS 2024 Global Health Community Chair
    Bioanalytical 101 Course Development
    Senior Bioassay Development Lead
    Gates Medical Research Institute
    Cambridge MA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------



  • 8.  RE: Editing Calibration Curves in Quantitative Ligand Binding Assays

    Posted 03-19-2024 12:42

    Dear Joleen

    Now it is getting complicated :)

    If the LLOQ-STD fails then the second lowest STD is the new LLOQ. That one has 20% acceptance criteria. 

    If you do not have a STD in between the Low QC and failed LLOQ, then the runs fails. That is LLOQ (STD1) - LowQC -  STD2 - STD3 etc  which now will be LowQC - STD 2(new LLOQ) - STD3 (run fails). QCs should always be 'covered' by a STD point. 

    If your second lowest STD is below Low QC then it is still acceptable. That is LLOQ (STD1) -  STD2 - LowQC - STD3 which now will be  STD2 (new LLOQ) - LowQC - STD3. 

    But you cannot extrapolate and use the anchor points as STD - as they are not STD but anchor points. So agree to your approach of having two STD below Low QC. 

    Best regards

    Marianne



    ------------------------------
    Marianne Scheel Fjording CEO
    Biolyzr Bioanalysis Excellence

    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------



  • 9.  RE: Editing Calibration Curves in Quantitative Ligand Binding Assays

    Community Leadership
    Posted 03-19-2024 15:58

    It is complicated, and we are in violent agreement!

    Hence the value of having some conversations in person where the details can be clarified in back-and-forth. When I was a newcomer to bioanalytical, there were lots of things that I didn't interpret quite right in the beginning.  



    ------------------------------
    Joleen White Ph.D.
    AAPS 2024 Global Health Community Chair
    Bioanalytical 101 Course Development
    Senior Bioassay Development Lead
    Gates Medical Research Institute
    Cambridge MA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------